Answers are grounded in this paper and cite their sources.
This model validates components of the MSKCC model with the addition of platelet and neutrophil counts and can be incorporated into patient care and into clinical trials that use VEGF-targeted agents.
No takes yet. Share an insight, caveat, or question.
Heng et al. (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: